Treatment of established tumors with intratumoral administration of reduced numbers of AdmCD40L-modified DCs.
The study was carried out in a fashion parallel to that in Figure 2, but with administration of 10% the number of AdmCD40L-modified DCs. (A) Growth of CT26 tumors in Balb/c mice. Balb/c mice were injected in the flank with 2 × 105 CT26 tumor cells as described in Figure 2A (day 0). On day 8, the tumor-bearing mice received intratumor injections of 2 × 105 DCs that had been transduced in vitro with AdmCD40L (▪), AdNull (□), or PBS alone (Δ) at moi 40 for 24 hours. (B) Survival, CT26 tumors, Balb/c mice. Shown is the survival of animals in panel A. (C) Growth of B16 tumors in C57Bl/6 mice. The study was identical to that described in panel A, except for the different tumor type and its number; ie, 5 × 105 B16 cells were used as described in Figure2C. (D). Survival, B16 tumors, C57Bl/6 mice. Similar to B, using mice in panel C. For panels A and C, the size of each tumor was assessed 3 times per week, and is reported as the average tumor area (mm2) ± standard error of n = 5 mice per group. Asterisks indicate significant differences at 95% confidence limits between AdmCD40L-transduced DCs and all other surviving groups. For panels B and D, survival was recorded as the percentage of animals in each group (Kaplan-Meier analysis, for both panels, P < .05 AdmCD40L compared with all other groups). In all panels, controls included tumor-bearing mice without any treatment (□).
